Chardan Capital Positive on Hemispherx (HEB) Following Expanded Ebola Collaborations

October 3, 2014 8:45 AM EDT
Get Alerts HEB Hot Sheet
Price: $1.80 --0%

Rating Summary:
    2 Buy, 1 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE

Chardan Capital affirms its Buy rating and $3 price target on Hemispherx BioPharma (AMEX: HEB) following a recent company update and expanded Ebola collaborations.

Analyst Ling Wang offered the following commentary:

  • HEB expanded research on potential Ebola treatments to five Institutional collaborators. The five collaborators include National Institutes of Allergy and Infectious Disease (NIAID); a branch of the NIH; the United States Army Research Institute in Infectious Disease (USAMRIID); the Swiss Department of Defense (Spiez Lab); Howard University, Washington, DC; and a US-based facility with biosafety
  • level 4 (BSL-4) capabilities with whom a Sponsor Research Agreement is currently being negotiated. Recall HEB has previously announced a collaboration with the USAMRIID for exploring Alferon against the deadly Ebola virus.
  • HEB’s two platforms has unique characteristics in fighting Ebola. Both Alferon and Ampligen are host based and therefore less subject to the evasive aspects of viral mutation. They both have demonstrated antiviral activity in a wide variety of DNA and RNA viruses in pre-clinical testing and safety in both animal and human clinical studies. The two products can work together under synergistic mechanisms. Additionally, both products can be made available immediately and in large quantity under GMP conditions. They also have flexible administration routes. The IV and IM delivery can be used for seriously ill patients while the nasal and oral delivery can be used to protect larger populations.
  • Ampligen Phase I data in Flu was recently published. HEB recently announced a peer-reviewed publication, entitled “Intranasal Seasonal Influenza Vaccine and a TLR-3 Agonist, Rintatolimod, Induced Cross-Reactive IgA Antibody Formation Against Avian H5N1 and H7N9 Influenza HA in Humans” on the Journal of Vaccine (2014). The data have been previously presented. The combination of intranasal FluMist® and Ampligen generated specific secretory IgA responses of at least 4 fold over baseline against at least one of the homologous vaccine strains included in the vaccine in 92% of the study subjects. The addition of ampligen induced cross-reactive secretory IgA against highly pathogenic avian influenza virus strains H5N1, H7N9, and H7N3 with pandemic potential for humans. The study is in collaboration with the University of Alabama Vaccine Research Clinic, Birmingham, Alabama.

For an analyst ratings summary and ratings history on Hemispherx click here. For more ratings news on Hemispherx click here.

Hemispherx closed at $0.35 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Chardan Capital Markets